Viridian Therapeutics Inc.

NASDAQ: VRDN
Share price (12/20/24): $19.03
Market cap (12/20/24): $1.507 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

ended 09/30/23 Q3

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Registration of securities for employees

Prospectus supplement for primary offering

Ownership Filter

Perceptive Advisors LLC

Venrock Opportunities Fund, L.P.

Venrock Healthcare Capital Partners III, L.P.

Paradigm Biocapital Advisors LP

State Street Corporation

News Filter

Announces Positive Topline Results From Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients With Chronic Thyroid Eye Disease

Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Material Definitive Agreement, Financial Statements or Exhibits

Announces Positive Topline Results From Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients With Active Thyroid Eye Disease

Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC